Fed. Circ. Affirms Nix Of Novartis Dementia Patch Patents

Law360, New York (April 4, 2017, 4:31 PM EDT) -- The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision that the challenged claims of two Novartis patents covering the dementia patch Exelon were invalid as obvious, affirming a win for accused infringer Noven Pharmaceuticals.

The three-judge panel found that the PTAB had properly concluded that the asserted claims of U.S. Patent Nos. 6,316,023 and 6,335,031 would have been obvious from several different combinations of prior art references. The court rejected Novartis AG’s argument that the PTAB's decision could not stand because the...
To view the full article, register now.